Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.288
+0.008 (2.86%)
At close: Nov 20, 2024, 4:00 PM
0.296
+0.008 (2.78%)
After-hours: Nov 20, 2024, 7:40 PM EST
Oragenics Employees
Oragenics had 5 employees as of December 31, 2023. The number of employees decreased by 1 or -16.67% compared to the previous year.
Employees
5
Change (1Y)
-1
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,993,245
Market Cap
3.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| Oncternal Therapeutics | 30 |
| NovaBay Pharmaceuticals | 26 |
| Azitra | 10 |
| Artelo Biosciences | 6 |
| Synaptogenix | 5 |
| Lixte Biotechnology Holdings | 4 |
| Tharimmune | 3 |
OGEN News
- 4 weeks ago - Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewsWire
- 6 weeks ago - Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewsWire
- 6 weeks ago - Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 3 months ago - Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 3 months ago - Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range - GlobeNewsWire